Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir Alafenamide Fumarate for HBV Low-level Viremia
NCT04501224Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tenofovir alafenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Ratio of patients with undetectable hepatitis b virus DNA after treatment at 24 weeks, The changes of glomerular filtration rate at 144 weeks and 1 more. Status: unknown.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04501224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04501224.